Clinical Trials Logo

Clinical Trial Summary

This ring aimed to preserve an intra-hepatic porto-caval gradient inferior to 5 mm Hg during and after major hepatectomy (48h) to protect the liver during the initial phases of liver regeneration. Morphological features of MID-AVRTM allow its intra corporeal opening and percutaneously removal after an balloon inflation with 5 ml of physiological serum. MID-AVRTM had been developed in pig where it had proved its efficiency to improve liver function after 75% hepatectomy and its capacity to be removed percutaneously. Aim of this feasibility study (Phase I/II) is to prove in series of 3 evaluable patients (Phase A) then 6 evaluable patients (Phase B) that MID-AVRTM could be used in human without deleterious consequence. In phase A, MID-AVRTM is dispose around the portal vein before and during a major hepatectomy performed on healthy liver and removed before abdominal closure. If phase A results confirmed that MID-AVRTM well modulates portal pressure and is easily opened and removed by acute inflation, the phase B will be started. In phase B, MID-AVRTM will be dispose around the portal vein before major hepatectomy on healthy liver and conserved 48 hours before to be removed percutaneously at the operating room.


Clinical Trial Description

Preserving liver function is vital, especially after hepatectomy, the main curative treatment of liver tumor. An hepatectomy that preserved a remnant liver volume < 0.5% of the body weight is associated with a very high risk of post-operative liver failure. In such situation, liver volume is not sufficient to support local hemodynamic consequences of the hepatectomy that is responsible of intrahepatic endothelial cell injury that impaired liver function and regeneration. To date, preoperative vein embolization (PVE) associated or not to liver transection (ALPSS procedure) that increased future remnant liver from 20% to 90% is the only method to prevent this complication. Even this preparation is necessary for the moment, PVE increased cancer cell proliferation and is associated with lower recurrence free survival than without PVE. Despite a potential PVE, POLF occurred in 5% to 7% after major hepatectomy and stayed the first cause of death after hepatectomy. It has been demonstrated that portal pressure superior to 20 mm Hg and/or porto-caval gradient superior to 12 mm Hg at the end of hepatectomy was associated to the occurrence of POLF. Aim to avoid this acute intra hepatic portal hypertension associated to major hepatectomy that is associated with an early liver endothelial cell injury, we had developed an silicon ring to dispose around the portal vein that contained an circular inflatable balloon to narrow precisely the portal vein lumen (MID-AVRTM).

Phase A: Tolerance and functionality of MID-AVR during surgery Each procedure will be filmed. Phase B: Tolerance and functionality of MID-AVR after surgery Each procedure will be filmed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02390713
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Eric VIBERT, MD, PhD
Phone +33 (0)6 60 64 96 97
Email eric.vibert@pbr.aphp.fr
Status Recruiting
Phase Phase 1/Phase 2
Start date April 18, 2015
Completion date December 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03791190 - RCA for CRRT in Liver Failure and High Risk Bleeding Patients N/A
Recruiting NCT05989958 - The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure Phase 1
Completed NCT02557724 - Mobilization of Mesenchymal Stem Cells During Liver Transplantation
Recruiting NCT01698723 - A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus Phase 2
Completed NCT01425385 - Autoregulation Assessment During Liver Transplantation N/A
Completed NCT01404793 - SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation N/A
Completed NCT03864497 - Myocardial Perfusion Imaging in Liver Transplantation Candidates
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Completed NCT00287235 - Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS) N/A
Completed NCT03650920 - Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients N/A
Recruiting NCT05517668 - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Phase 2
Recruiting NCT05726032 - Empagliflozin in Patients With Cirrhosis and Ascites Phase 2
Recruiting NCT04548596 - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting NCT02331745 - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure Phase 4
Not yet recruiting NCT01961440 - Prognosis Scoring System for Acute-on-Chronic Liver Failure N/A
Active, not recruiting NCT01221454 - Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure Phase 2
Completed NCT00772148 - Pharmacokinetics of LCP-Tacroâ„¢ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients Phase 2
Completed NCT05592106 - Gd-EOB-DTPA-enhanced T1 Map for Predicting Postoperative Liver Failure
Not yet recruiting NCT06014320 - Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
Recruiting NCT04221672 - The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy Phase 3